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Alternative splicing is a key process underlying the
evolution of increased proteomic and functional
complexity and is especially prevalent in the mam-
malian nervous system. However, the factors and
mechanisms governing nervous system-specific
alternative splicing are not well understood. Through
a genome-wide computational and expression pro-
filing strategy, we have identified a tissue- and verte-
brate-restricted Ser/Arg (SR) repeat splicing factor,
the neural-specific SR-related protein of 100 kDa
(nSR100). We show that nSR100 regulates an exten-
sive network of brain-specific alternative exons
enriched in genes that function in neural cell differen-
tiation. nSR100 acts by increasing the levels of the
neural/brain-enriched polypyrimidine tract binding
protein and by interacting with its target transcripts.
Disruption of nSR100 prevents neural cell differentia-
tion in cell culture and in the developing zebrafish.
Our results thus reveal a critical neural-specific alter-
native splicing regulator, the evolution of which has
contributed to increased complexity in the vertebrate
nervous system.
INTRODUCTION
Recent high-throughput sequencing studies indicate that at least
95% of human multiexon genes produce alternatively spliced
transcripts (Pan et al., 2008; Wang et al., 2008). Alternative
splicing (AS) has played a major role in the evolutionary expan-
sion of proteomic and functional complexity underlying many
cellular processes and is especially prevalent in the vertebrate
nervous system, with emerging key roles in synaptogenesis,
neurite outgrowth, axon guidance, ion channel activity, and
long-term potentiation (Li et al., 2007; Ule and Darnell, 2006).898 Cell 138, 898–910, September 4, 2009 ª2009 Elsevier Inc.However, mechanisms that control neural-specific AS and that
underlie the evolution of increased nervous system complexity
are poorly understood.
Regulated AS requires the interplay of cis- and trans-acting
factors that repress or activate splice site selection (Blencowe,
2006; Wang and Burge, 2008). RNA binding domain (RBD)-con-
taining proteins belonging to the heterogeneous nuclear ribonu-
cleoprotein (hnRNP) family and a superfamily of alternating Arg/
Ser (RS) domain-containing proteins, referred to as ‘‘SR family’’
and ‘‘SR-related’’ proteins, act widely to control AS. Members of
these protein families can either repress or promote the forma-
tion of active splicing complexes (spliceosomes), often depend-
ing on the location of cognate binding sites within exon or intron
sequences (Lin and Fu, 2007; Martinez-Contreras et al., 2007).
SR family proteins contain one or two N-terminal RNA recog-
nition motifs and a C-terminal RS domain, whereas SR-related
proteins, which include factors that are pivotal in the control of
sex determination in Drosophila, contain RS domains but may
or may not contain RBDs (Lin and Fu, 2007). Phosphorylated
RS domains are thought to function in the formation of protein-
protein and protein-RNA interactions required for spliceosome
assembly (Shen et al., 2004; Wu and Maniatis, 1993). Approxi-
mately 40 mammalian RS domain proteins have been implicated
in splicing (Lin and Fu, 2007). Although ubiquitously expressed, it
has been proposed that variable levels of these proteins may
contribute to cell- and tissue-dependent AS patterns (Hanamura
et al., 1998; Zahler et al., 1993).
To date, only RBD proteins that lack RS domains have been
shown to possess tissue-restricted expression patterns and
several such proteins play important roles in cell- and tissue-
specific AS (Li et al., 2007). These include the neuronal-specific
Nova-1/2 and HuB proteins, the neuronal and muscle-expressed
Fox-1/2, CELF/CUGBP, and MBNL family proteins, and the
neural, myoblast, and testis-expressed nPTB protein (also
referred to as brPTB and PTBP2). nPTB is a paralog of the widely
expressed PTB (also hnRNPI/PTBP1) splicing repressor protein
(Ashiya and Grabowski, 1997; Markovtsov et al., 2000; Polydor-
ides et al., 2000). A switch from PTB to nPTB expression during
neuronal differentiation has been implicated in regulating
neuronal AS (Boutz et al., 2007; Makeyev et al., 2007; Spellman
et al., 2007). Previous evidence has suggested that this switch
results in the formation of ‘‘less repressive’’ nPTB-bound splicing
complexes that are responsive to positive-acting factors in
neurons (Markovtsov et al., 2000). However, the mechanisms
controlling neuronal-specific exon inclusion patterns in conjunc-
tion with nPTB have remained unclear.
Several tissue-restricted AS factors are involved in controlling
subsets of exons that are enriched in functionally-related genes
(Boutz et al., 2007; Kalsotra et al., 2008; Ule et al., 2005; Yeo
et al., 2009; Zhang et al., 2008). For example, through binding
to clusters of YCAY motifs distributed within specific exon and
intron zones, Nova2 can positively or negatively regulate 7%
of neural-specific alternative exons in genes that function in
the synapse and in axon guidance (Licatalosi et al., 2008; Ule
et al., 2005). How AS specificity is established for the vast
majority of other neural-specific exons is not understood,
however. Moreover, the specific biological processes controlled
by the majority of neural-specific exons are also not well under-
stood.
We have identified a tissue- and vertebrate-restricted RS
domain protein, referred to as the neural-specific SR-related
protein of 100 kDa (nSR100). Knockdown of nSR100 disrupts
the inclusion of a large set of nervous system-specific alternative
exons that are significantly enriched in genes with critical func-
tions in neural cell differentiation. Consistent with this molecular
programming function, nSR100 is required for neural cell differ-
entiation in vivo. nSR100 forges neural specificity in AS by
activating nPTB expression and, in conjunction with nPTB, by
binding directly to its regulated target transcripts. nSR100 thus
acts in a multifaceted manner in the tissue-specific regulation
of a network of exons associated with neural cell differentiation
and the evolution of vertebrate nervous system complexity.
RESULTS
A Genome-wide Screen Identifies a Vertebrate
and Neural-Specific SR-Related Protein
To identify mammalian SR-related proteins with the potential to
function as cell type- and/or tissue-specific splicing regulators,
we used a computational procedure for the genome-wide sur-
veying of RS domain protein-encoding genes (Figure 1A; refer
to the Supplemental Experimental Procedures available online).
Applying this procedure to a set of nonredundant mouse cDNAs
resulted in the identification of 112 known or putative new RS
domain genes (see Table S1).
Manual annotation revealed that 36% (40/112) of the RS
domain genes have a function associated with splicing and
15% (17/112) have functions associated with RNA polymerase
II-dependent transcription and mRNA 30-end processing, which
are coupled to and can influence splicing (Figure 1A). Remark-
ably, 32% (36/112) of the identified genes have no annotated
function. Given that more than one third of the annotated genes
have known functions in splicing, many of the previously unchar-
acterized genes likely also participate in splicing. Moreover,
since 96% (108/112) of the predicted mouse proteins encoded
by these genes have a closely related human ortholog witha computationally defined RS domain, the majority of these
proteins likely have conserved functions.
Using microarray profiling data we analyzed expression
patterns of the computationally-mined RS domain genes in 50
diverse mouse cell and tissue types (Figures 1B and S1). Many
of these genes appear to be widely but variably expressed,
which is consistent with previous observations (Hanamura
et al., 1998; Zahler et al., 1993). Interestingly, hierarchical clus-
tering analysis reveals that two prominent subsets of genes
display distinct spatiotemporal regulation. One subset displays
elevated expression in whole embryo and embryonic head
samples from days 9.5 to 14.5 and the other displays elevated
expression in adult nervous system tissues (Figure 1B, boxed
region; and Figure S1).
We focused our attention on an RS domain gene (NM_026886;
human NM_194286/KIAA1853) displaying increased expression
in the developing embryo and highly restricted expression in adult
nervous system and sensory organ tissues (Figure 1B). The
NM_026886 open reading frame (ORF) is predicted to encode
a 608 amino acid protein of 68 kDa that contains prominent
runs of alternating SR/RS repeats (Figure 1C). Although the
protein encoded by theNM_026886 gene has not been function-
ally characterized, it has been detected as a tumor antigen in
pediatric patients with medulloblastomas (Behrends et al., 2003).
In addition to its neural-restricted expression pattern, a feature
of the NM_026886 ORF that distinguishes it from previously
characterized RS domain proteins is that it is highly conserved
only in vertebrate species (Figure S2 and data not shown). The
NM_026886 ORF and its orthologs lack a canonical RBD. The
only region of significant similarity with other protein sequences
is a sequence spanning amino acids 490 to 521 that is identical
to amino acids 573 to 604 in the human SRm300 splicing coac-
tivator subunit-like gene (SRm300-like/SRRM2L). These results,
together with additional experiments described below, indicate
that the NM_026886 gene encodes the neural-specific SR-
related protein of 100 kDa, which we refer to below as nSR100.
Distribution of nSR100
RT-PCR assays confirmed that nSR100 mRNA is strikingly
enriched in multiple brain regions and sensory organ tissues
(Figure 1D). A rabbit polyclonal antibody raised against a GST
fusion protein containing amino acids 1 to 82 of human
nSR100 recognizes a band that migrates at 100 kDa in
neuronal-derived cell lines (mouse Neuro2a and human Weri-
RB1), but which is not expressed in nonneural mouse or human
cell lines (C2C12, NIH 3T3, HEK293-T, and HeLa) (Figure 1E).
The higher than expected mobility of nSR100 is typical of SR
proteins because RS domains are generally highly phosphory-
lated. Confirming the phosphorylation status of nSR100, myc
epitope-tagged nSR100 protein expressed in Neuro2a cells
was detected using the monoclonal antibody mAb104, which
specifically recognizes a phosphoepitope shared among SR
proteins (data not shown; Zahler et al., 1992).
To establish whether nSR100 is expressed in specific neural
cell types, adult mouse neural progenitor cells were differenti-
ated in vitro into neurons and glia, the latter comprising astrocyte
and oligodendrocyte populations. These neural cell populations
were coimmunostained with anti-nSR100 antibody and anti-bIIICell 138, 898–910, September 4, 2009 ª2009 Elsevier Inc. 899
tubulin (neuronal marker) or anti-glial fibrillary acidic protein (glial
marker) antibodies. nSR100 is highly enriched in the nuclei of the
neuronal but not glial cell populations because prominent
nSR100 nuclear staining (marked by coincident Hoechst stain-
ing) is detected only in the anti-bIII tubulin-positive cells (Fig-
ure 2A). Together, these experiments indicate that after neural
progenitor cells differentiate, nSR100 primarily functions in the
nuclei of neurons.
nSR100 Is Required for Neural Cell Differentiation
We next asked whether nSR100 functions in the differentiation of
cultured Neuro2a cells, murine embryonic stem cells (ESCs), and
adult neural stem cells. Neuro2a cells produce long extensions
Figure 1. Identification and Expression
Characteristics of nSR100
(A) (Left) Computational strategy for the genome-
wide survey of mouse RS domain protein genes.
(Right) Functional associations of computationally
defined mouse RS domain protein genes (refer to
Table S1 for a full list and description).
(B) Clustergram showing relative mRNA expres-
sion levels of RS domain protein genes (y axis)
across 50 mouse cell and tissue types (x axis).
Color scale indicates fold expression relative to
the median value across the data set. The
enlarged portion of the clustergram shows RS
domain protein genes with elevated expression
in neural tissues with NM_026886/Riken cDNA
1500001A10 (nSR100) indicated. Refer to
Figure S1 for an enlarged view of the entire cluster-
gram with all gene names indicated.
(C) Translated sequence of mouse nSR100 (from
NM_026886), with RS/SR dipeptides highlighted.
The underlined region indicates amino acids
(1–82) used to generate an anti-nSR100 polyclonal
antibody. The boxed region is identical to a se-
quence in the SRm300 splicing coactivator
subunit-like protein (SRRM2L).
(D) RT-PCR analysis of mouse nSR100 mRNA
expression across 20 diverse tissues and several
brain subregions, relative to Gapdh mRNA expres-
sion in the same samples.
(E) Western blot of nonneuronal and neuronal-
derived cell line lysates probed with an anti-
nSR100 antibody. Arrowheads indicate detection
of nSR100 (see also Figures 2 and 5) and the
asterisk indicates a cross-reacting species.
known as neurites in the presence of ret-
inoic acid (RA). ESCs can be differenti-
ated to produce neural stem and progen-
itor cells (Tropepe et al., 2001), and neural
stem cells isolated from adult mouse
brains can be differentiated into all major
cell types of the nervous system in culture
(Morshead et al., 1994). These three
systems allowed us to investigate the
role of nSR100 during different aspects
of neural differentiation in vitro.
In Neuro2a cells, nSR100 is expressed prior to induced differ-
entiation and does not significantly increase at 48 hr after induc-
tion (data not shown). To test whether nSR100 is required for
neurite extension, lentivirus-delivered short hairpin RNAs
(shRNAs) were used to generate undifferentiated Neuro2a cells
with constitutively reduced (by 70%–75%) levels of nSR100,
relative to undifferentiated cells expressing a control shRNA tar-
geted to GFP (Figure 2B). The reduced levels of nSR100 had no
significant impact on cell viability (Figure S3 and data not shown),
but dramatically impaired neurite extension (Figures 2C and S4).
Within 24 hr after induction with RA, >35% of control shRNA-
treated cells extended long neurites, whereas only 5% of
the nSR100 shRNA-expressing cells extended processes of900 Cell 138, 898–910, September 4, 2009 ª2009 Elsevier Inc.
comparable length (Figures 2C and S4). In contrast, knockdown
of a widely expressed SR-related splicing factor, SRm160, re-
sulted in reduced viability of undifferentiated Neuro2A cells (Fig-
ure S3). These findings suggest that nSR100 is required for
specific steps during neural differentiation, rather than for
a more general role associated with cell viability.
nSR100 mRNA levels increase when ESCs are induced to
differentiate to form neural progenitor cells (Figure 2D). Cultured
ESCs were induced to proliferate and aggregate into spherical
cell populations known as ‘‘neurospheres,’’ which contain neural
progenitor cells. When stably expressing control or nSR100-tar-
geting shRNAs prior to induced differentiation, no discernable
differences in morphology or proliferation were observed (data
not shown). However, when induced, nSR100 knockdown ESCs
formed 90% fewer neurospheres than did the control shRNA-
treated cells (Figure 2E). Similar results were observed upon
knockdown of nSR100 in induced adult-derived neural stem cells
(Figure 2E). Two independent shRNAs targeting nSR100 led to
similar results, indicating that the effects are specific and not
due to off-target effects (data not shown; see also below and
Figure 3D). These results therefore indicate that nSR100 plays
a critical role in neural stem and progenitor cell formation and/or
proliferation, in addition to a role in neurite extension.
Figure 2. nSR100 Is Required for Neural Cell Differen-
tiation
(A) Confocal microscopy images of differentiated neural
progenitor cells coimmunostained with anti-b-III tubulin (red,
top panels), anti-glial fibrillary acidic protein (anti-GFAP; red,
bottom panels), and anti-nSR100 (green, top and bottom
panels) antibodies. Nuclei are stained using Hoechst dye
(blue, top and bottom panels). All b-III tubulin-positive neurons
show nSR100 staining. Scale bar represents 25 mm.
(B) Western blot probed with anti-nSR100 antibody showing
lysates from Neuro2a cells stably expressing control shRNA
(lane 1) or nSR100-targeting shRNA (lane 2). a-tubulin levels
were used as a loading control.
(C) Quantification of percentage of shRNA-expressing
Neuro2a cells extending long neurites (measured as greater
than three cell body lengths) under normal culture conditions
and differentiation conditions. Values represent averages
from three independent experiments ± one standard devia-
tion. Figure S3 shows representative brightfield images of
Neuro2a cells from each treatment.
(D) RT-PCR analysis of nSR100 mRNA levels in ES, neural
progenitor (NP), and differentiated neurons and glia (lanes 1,
2, and 3, respectively). Gapdh mRNA levels are shown for
comparison.
(E) Quantification of relative percentage of primary neuro-
spheres formed by differentiating ESCs expressing control
or nSR100-targeting shRNAs or secondary neurospheres
from adult neural stem cells expressing control or nSR100-tar-
geting shRNAs. Values represent the averages from four inde-
pendent experiments ± one standard deviation.
nSR100 Regulates a Network
of Brain-Specific Alternative Exons
We next investigated whether the effects of
nSR100 knockdown on neural cell differentiation
are associated with the deregulation of specific
AS events. PolyA+ RNA from control and nSR100
shRNA-expressing, undifferentiated Neuro2a cells was profiled
using an AS microarray (Figure 3A; refer to the Supplemental
Experimental Procedures). AS patterns in adult mouse whole
brain and five nonneural tissues were profiled in parallel
(Figure 3B). Confidence-ranked percent exon exclusion esti-
mates (%ex; the percentage of transcripts skipping a profiled
alternative exon) were determined (Pan et al., 2004). In order to
enrich for physiologically relevant events, we focused our anal-
ysis on exons displaying both nSR100-dependent regulation in
Neuro2a cells and differential splicing between brain and non-
neural tissues (Figure 3B and data not shown).
One hundred and fifteen high-confidence AS events met the
above criterion and displayed %ex differences of at least 15%
upon nSR100 knockdown (Table S2). Seventy percent (81/115)
displayed increased exon skipping upon knockdown of nSR100,
and RT-PCR experiments validated 81% (21/26) of these events
(Figures 3C and S5; data not shown). Only one of seven tested
events displaying increased exon inclusion upon nSR100 knock-
down was validated, although the change in %ex was relatively
modest (data not shown). Moreover, only 6% (3/52) of predicted
non-nSR100 targets were found to change upon nSR100 knock-
down, indicating a low false-negative detection rate (data not
shown). The reduced levels of exon inclusion observed uponCell 138, 898–910, September 4, 2009 ª2009 Elsevier Inc. 901
knockdown of nSR100 persisted following RA-induced differen-
tiation in all of five analyzed cases (Figure S6). These results indi-
cate that nSR100 acts predominantly to promote alternative
exon inclusion prior to the formation of neurites in Neuro2a cells.
To address whether the altered exon inclusion levels in the
knockdown experiments were specifically caused by the
shRNA-reduced expression of nSR100, an RNAi-resistant form
of nSR100 mRNA was stably expressed in the nSR100 shRNA
knockdown line and splicing levels of several alternative exons
were monitored by RT-PCR assays. Expression of nSR100 in
the knockdown line, which was confirmed by western blotting
(Figure 3D, top panel, lanes 5 and 6), fully restored the inclusion
of the tested alternative exons (Figure 3D, lower three panels,
compare lanes 5 and 6 with 1–4). In contrast, stable expression
of another SR protein, SF2/ASF, did not function in this manner
Figure 3. nSR100 Regulates a Network of
Neural-Specific Alternative Splicing Events
(A) Strategy used for the global analysis of nSR100-
regulated AS. Black lines represent exon body and
exon junction probes used to monitor AS levels on
a custom microarray.
(B) Heatmap displaying microarray %ex values for
a subset of nSR100-regulated alternative exons.
Columns show microarray %ex predictions from
profiled adult mouse tissues and Neuro2a cells
expressing control or nSR100-targeting shRNAs,
and rows represent %ex predictions for individual
nSR100-regulated exons undergoing increased
skipping upon nSR100 knockdown. The AS
events are sorted in descending order according
to the magnitude of the %ex values in the control
shRNA-expressing Neuro2a cells. All AS events
displayed have detectable expression in whole
brain and at least two other tissues; white indi-
cates expression was below the threshold level
used to derive %ex estimates.
(C) RT-PCR assays using primers specific to the
constitutive exons flanking nSR100-regulated
alternative exons in Daam1, Clasp2, Dock4, and
Elmo2 transcripts. Bands corresponding in size
to exon-included and exon-skipped isoforms are
indicated.
(D) Neuro2a cell lines stably expressing control
(lanes 1, 3, and 5) or nSR100 targeting (lanes 2,
4, and 6) shRNAs and pWZL-hygro empty vector
(lanes 1 and 2), T7 epitope-tagged SF2/ASF (lanes
3 and 4), or nSR100 cDNA (lanes 5 and 6). Top
three panels show western blots monitoring the
expression of nSR100 (top panel), T7-tagged
SF2/ASF (middle panel), and a-tubulin (bottom
panel). Bottom three panels show RT-PCR assays
using primers to specifically monitor AS in the
Daam1, Zdhhc20, and Asph transcripts.
(Figure 3D, all panels, lanes 3 and 4).
These results support the conclusion
that nSR100 functions specifically to pro-
mote exon inclusion. The nSR100-regu-
lated exons were estimated to represent
11% of AS events identified as being
differentially regulated in nervous system
tissues by microarray profiling (see the Supplemental Experi-
mental Procedures).
A Gene Ontology annotation enrichment analysis revealed that
genes containing nSR100-regulated exons are significantly en-
riched in functions associated with membrane dynamics and
cytoskeleton remodeling (Table S3), processes that are critical
for the differentiation of neurons and neurite extension. Also sup-
porting functional significance, nSR100-regulated alternative
exons are significantly more often frame preserving (66.7%
versus 45.4%; p < 0.005, Fisher’s exact test) and conserved in
human transcripts (62.8% versus 24.5%; p < 109, Fisher’s exact
test) than are the other profiled exons (Table S2). These results
thus reveal that nSR100 regulates a network of mostly con-
served AS events in functionally related genes that play impor-
tant roles in the formation and function of the nervous system.902 Cell 138, 898–910, September 4, 2009 ª2009 Elsevier Inc.
An nSR100 Regulatory Code
To gain insight into the mechanism by which nSR100 regulates
neural-specific AS, we identified motifs of 5–10 nucleotides in
length that are significantly enriched in the regulated alternative
and adjacent constitutive exons and in the 500 nucleotides of
intron sequence that flank these exons (Figure 4A; refer to the
Supplemental Experimental Procedures). The most enriched
and prevalent motifs are C/U rich and are specifically located
within the upstream and/or downstream intronic regions flanking
nSR100-regulated exons (Figure 4A, FDR-corrected p value
<0.01). Additional high scoring motifs were identified using the
same procedure (Figure S7; see the Discussion).
As a parallel approach to defining cis-regulatory elements, we
generated an AS minigene reporter (Daam1 FL) consisting of a
2.8 kb genomic fragment encompassing nSR100-regulated
Daam1 exon 16 (Figure 4B). Daam1 is required for neurite forma-
tion and outgrowth during development (Matusek et al., 2008),
and skipping of exon 16 in nonneuronal cells is predicted to
disrupt a formin homology-like domain that likely mediates
Figure 4. Elements of an nSR100 Regulatory Code
(A) Pyrimidine-rich motifs identified as significantly enriched in
the 500 nucleotides of upstream and/or downstream intron
sequence flanking nSR100-regulated alternative exons. Motifs
with FDR-corrected hypergeometric p value scores <0.01 are
shown.
(B) (Left) RT-PCR assays monitoring AS levels of Daam1 exon
16 minigene reporters transfected in NIH 3T3 cells and in
Neuro2a cells expressing control or nSR100-targeting
shRNAs. The lengths of upstream and downstream intron
sequence included in each minigene reporter are indicated
above the gel. (Right) The diagram indicates the length of
Daam1 genomic DNA sequence included in each minigene
reporter (green bars) and the degree of AS repressor activity
associated with these regions (indicated by pluses).
(C) RT-PCR assays monitoring the AS levels of transcripts
derived from additional Daam1 minigene reporters in Neuro2a
cells expressing control shRNA or nSR100-targeting shRNAs.
Gels on the left display AS patterns observed with reporters
containing either 271 or 250 nucleotides of upstream intron
sequence and 50 nucleotides of downstream intronic
sequence. Gels on the right display AS patterns from reporters
containing 483 and 146 nucleotides of upstream and down-
stream sequence, respectively, when region 271 to 250
and additional upstream pyrimidine nucleotides (up to posi-
tion 280; see Figure S8) are unchanged (483 to 146) or
substituted (483 to 146 mut) with an unrelated sequence
of equal length. Percent exon inclusion levels (%inc) are
shown below gel images in (B) and (C).
important interactions with signaling partners and
components of the cytoskeleton.
The Daam1 FL minigene reporter recapitulated
the AS pattern of endogenous Daam1 transcripts,
with the alternative exon displaying more inclusion
in Neuro2a cells expressing control shRNAs rela-
tive to cells expressing shRNAs targeting nSR100
(Figure 4B). Moreover, the inclusion of Daam1
exon 16 appears to be neural specific because
reporter transcripts expressed in NIH 3T3 and
myoblast C2C12 cell lines undergo complete
exon skipping (Figure 4B and data not shown). These results
indicate that cis elements required for nSR100-dependent regu-
lation of Daam1 exon 16 are contained within the 2.8 kb Daam1
FL reporter genomic fragment.
Deletion of the Daam1 reporter intron sequences followed by
refined mutagenesis revealed a region 250 to 271 nucleotides
upstream of the alternative exon that significantly affected
nSR100-dependent exon inclusion (Figures 4B and 4C). Deletion
of this region resulted in increased exon inclusion. This effect was
most pronounced in the nSR100 knockdown cell line (Figure 4C,
compare lanes 1 and 2). Similar effects were observed when this
region and neighboring nucleotides were substituted with unre-
lated sequence (Figure 4C, compare lanes 3 and 4). These results
indicate that this 21 nucleotide region contains a strong repressor
element that results in the skipping of Daam1 exon 16 in the
absence of nSR100. nSR100 thus appears to play a critical role
in overcoming the repressive effects exerted by this element.
In agreement with our computational analysis, the 271 to
250 AS repressor region and its neighboring nucleotides areCell 138, 898–910, September 4, 2009 ª2009 Elsevier Inc. 903
highly enriched in pyrimidine nucleotides (Figure S8) and two of
the computationally identified motifs overlap this region. There-
fore, both approaches to defining cis-regulatory elements
strongly implicate pyrimidine-rich motifs in nSR100-dependent
splicing regulation.
nSR100 Promotes nPTB Protein Expression
Pyrimidine-rich motifs have previously been implicated in neural-
specific regulation of AS involving PTB (also hnRNPI/PTBP1),
a widely acting splicing repressor, and its neural-enriched
paralog nPTB (also brPTB/PTBP2) (see the Introduction and
below). The switch from PTB to nPTB during neuronal differenti-
ation is regulated in part by a neuronal miRNA miR-124 (Makeyev
et al., 2007). In nonneuronal cells, expression of PTB results in
skipping of exon 10 in nPTB pre-mRNA and this leads to the
introduction of a premature termination codon that elicits
nonsense-mediated mRNA decay of nPTB transcripts (Boutz
et al., 2007; Makeyev et al., 2007; Spellman et al., 2007). In
neuronal cells, miR-124 repression of PTB facilitates nPTB
exon 10 inclusion and productive nPTB expression.
To address whether PTB and/or nPTB are involved in the regu-
lation of nSR100-dependent AS events, we knocked down these
factors individually or together using siRNAs (Figure 5A). As ex-
pected, knockdown of PTB led to increased inclusion of exon 10
in nPTB pre-mRNA. RT-PCR assays were then used to monitor
the AS levels of Daam1 exon 16 and nine randomly selected,
RT-PCR-validated nSR100-regulated exons (Figures 5A and S9).
In contrast to the effect of nSR100 knockdown, Daam1 exon
16 and eight of the nine other exons displayed increased levels
of inclusion when PTB levels were reduced and to a lesser extent
when nPTB was reduced. Simultaneous depletion of nPTB and
PTB resulted in levels of exon inclusion that were at least as
high and in some cases higher than the levels observed when
PTB was knocked down alone. These findings establish a wide-
spread role for PTB/nPTB in the repression of nSR100-depen-
dent AS events. More specifically, these proteins promote
skipping of the same exons that require nSR100 for neural-
specific inclusion. Consistent with a previous proposal (Markovt-
sov et al., 2000), the less repressive activity of nPTB relative to
PTB suggests that it might facilitate neural-specific AS by estab-
lishing complexes that are more permissive to positive acting
factors.
To further explore the functional relationship between nSR100
and PTB/nPTB proteins, we next asked, (1) does nSR100
promote neural-specific AS by regulating the relative levels of
nPTB and PTB proteins, (2) do PTB/nPTB bind directly to C/U-
rich sequences involved in mediating nSR100-dependent regu-
lation, and (3) does nSR100 act in a dominant-positive manner
to counteract the repressive activity of nPTB?
Our microarray profiling experiments (Figure 3) in fact pre-
dicted increased skipping of nPTB exon 10 in Neuro2a cells
depleted of nSR100 (Table S2). Confirming this prediction,
knockdown of nSR100, while not altering PTB mRNA or protein
levels, resulted in decreased inclusion of nPTB exon 10 and,
consequently, reduced levels of nPTB mRNA and protein
(Figure 5B). Consistent with the repressive effects of PTB and
nPTB on nSR100-regulated exons, both proteins bind directly
and specifically to C/U-rich intron regions upstream of Daam1904 Cell 138, 898–910, September 4, 2009 ª2009 Elsevier Inc.exon 16 (Figures S8 and S10). However, essentially no binding
to these regions was observed when comparable levels of puri-
fied nSR100 (Figure S10A) were added alone or in combination
with PTB or nPTB (Figure S11A). At much higher amounts of
nSR100, a low level of binding was observed although this ap-
peared to be relatively less specific (Figure S11A).
Further supporting a critical role for nSR100 in promoting
neural-specific exon inclusion of PTB/nPTB repressed exons,
when nPTB is overexpressed in Neuro2a cells, increased skip-
ping of Daam1 exon 16 is observed (Figure S11B). However,
simultaneous overexpression of nSR100 and nPTB effectively
alleviates the repressive activity of nPTB and results in 100%
inclusion of Daam1 exon 16 (Figure S11B). This confirms that
nSR100 is required to promote the inclusion of neural-specific
exons in cells that also express nPTB.
nSR100 Promotes Neural-Specific Exon Inclusion
In Vitro
nSR100 appears to act together with nPTB and possibly other
factors to promote neural-specific exon inclusion. We next
asked whether nSR100 functions in this manner in vitro.
Splicing-competent extracts were prepared from neuronal
Weri-Rb1 cells and efficiently (>90%) immunodepleted of
nSR100 using affinity-purified anti-nSR100 antibody (Figure 1E)
or mock-depleted using rabbit anti-mouse antibody (Figure 5C,
compare lanes 1 and 2 with lanes 3 and 4). A T7-transcribed,
three-exon pre-mRNA consisting of Daam1 exon 16 with 280
nucleotides of upstream and 145 nucleotides of downstream in-
tronic sequence, inserted between strong constitutive exons
derived from an adenovirus pre-mRNA substrate (MINX), was
assayed for splicing activity in these extracts.
This substrate splices efficiently in the mock-depleted Weri
extract, producing exon 16 included and skipped transcripts
(Figure 5D, lane 2). When nSR100 is immunodepleted, in-
creased exon 16 skipping is detected (Figure 5D, lane 3),
whereas addition of increasing amounts of purified nSR100
protein results in 100% inclusion of exon 16 (Figure 5D, lanes
4–8). This activity is specific because addition of comparable
levels of the SR family protein SF2/ASF (Figure S10A) does
not result in a substantial increase in exon 16 inclusion (Fig-
ure 5D, compare lanes 4–8 with 9–13). Moreover, addition of
purified nSR100 protein to a HeLa splicing extract does not
promote the inclusion of Daam1 exon 16 (Figure 5E, compare
lanes 2–5 with 6–9). These results demonstrate that nSR100
functions to promote the inclusion of Daam1 exon 16 in a neural
cell extract. However, consistent with the results demonstrating
that nSR100 functions in part by promoting the expression of
nPTB, it is not sufficient to promote a neural-specific splicing
pattern in a nonneural extract.
We next performed in vitro and in vivo UV crosslinking followed
by immunoprecipitation (CLIP; Supplemental Experimental
Procedures) to establish whether, in the context of other cellular
factors, nSR100 interacts directly and specifically with its regu-
lated target pre-mRNAs. Anti-nSR100 antibody specifically en-
riched a radiolabeled protein approximately the size of nSR100
from Weri extract incubated and crosslinked in the presence of
a 32P-UTP-labeled Daam1 RNA consisting of the upstream in-
tronic regulatory sequences (Figure 5F, compare lanes 2 and 4).
Figure 5. nSR100 Functions by Promoting
nPTB Expression and by Binding to its
Regulated Target Transcripts
(A) (Left) RT-PCR assays monitoring steady-state
mRNA expression levels and AS patterns of
nSR100, PTB, nPTB, and Daam1 transcripts in
Neuro2a cells transfected with control siRNAs
(lane1) or siRNAs targeting PTB, nPTB, or both of
these factors. Expression levels of Gapdh tran-
scripts were monitored to control for recovery
and loading.
(B) RT-PCR assays monitoring the expression
levels and/or AS patterns of nSR100, PTB, nPTB,
and Gapdh transcripts in Neuro2a cells expressing
control or nSR100-targeting shRNAs (top four
panels). Western blotting (bottom three panels)
was performed using lysates from the cells as-
sayed in (A) and antibodies capable of detecting
PTB paralogs (a-pan-PTB) and nPTB specifically
(a-nPTB) (refer to Supplementary Data for addi-
tional details). Tubulin levels were monitored to
control for sample recovery and loading.
(C) Immunodepletion of nSR100 from splicing
competent Weri whole cell extracts. Western blot-
ting on extracts immunodepleted of nSR100
(DnSR100) using anti-nSR100 antiserum (lane 4)
and mock-immunodepleted (mock) using rabbit
anti-mouse antibody (lane 3). Two different
amounts of total extract, corresponding to 100%
and 10% of the amounts of extract loaded in lanes
3 and 4, are shown in lanes 1 and 2, respectively.
(D) Purified recombinant nSR100 protein specifi-
cally promotes the inclusion of Daam1 exon 16
in vitro. A T7 pre-mRNA transcript (see diagram)
consisting of strong constitutively spliced 50 and
30 exons (MINX) and Daam1 alternative exon 16,
flanked by its native upstream and downstream
intron sequence, was incubated in the Weri
extracts (C) supplemented with and without re-
combinant proteins (Figure S10A) and splicing
activity was monitored by RT-PCR assays and
primers specific for the MINX exons. The
DnSR100 extract was supplemented with 10, 25,
50, 100, and 200 ng of purified nSR100 protein
(lanes 4–8, respectively) or with 5, 12.5, 25, 50,
and 100 ng of SF2/ASF protein (lanes 9–13).
Splicing of the Daam1 pre-mRNA in the mock
and DnSR100 Weri extracts without added
proteins is shown in lanes 2 and 3, respectively.
Lane 1 shows input pre-mRNA.
(E) Recombinant nSR100 protein is not sufficient to promote Daam1 exon 16 inclusion in a nonneural origin (HeLa) cell extract. Weri and HeLa cell extracts were
incubated without (lanes 2 and 6) or with 10, 25, and 50 ng nSR100 protein, and splicing activity was monitored as described in (D). Input pre-mRNA is shown in
lane 1.
(F) Anti-nSR100 antiserum enriches a protein of the approximate size of nSR100 that is UV crosslinked to Daam1 intronic regulatory sequences. A radiolabeled T7
transcript consisting of the upstream intronic regulatory region (nucleotides 280 to 1) of Daam1 exon 16 was incubated under splicing conditions in Weri cell
extracts, without (lane 1) or with (lane 2) UV exposure, prior to extensive treatment of the extracts with RNase. Proteins in these extracts were immunoprecipitated
with anti-nSR100 (lane 4) or control (lane 3; rabbit anti-mouse antibodies). Total extract and immunoprecipitated proteins were separated on an SDS-PAGE gel,
which was dried and exposed to film. The asterisk denotes the crosslinked protein species migrating at approximately the same location as nSR100.
(G) CLIP reveals that nSR100 interacts directly with endogenous pre-mRNA transcript regions overlapping nSR100 regulated exons. Neuro2a cells were exposed
(lanes 1–5) or not exposed (lanes 6–10) to UV light. Immunoprecipitation was performed from lysates prepared from the cells using anti-nSR100 antibody (lanes 3,
5, 8, and 10) or a control (rabbit anti-mouse) antibody (lanes 2, 4, 7, and 9). Detection of immunoprecipitated pre-mRNA regions was performed using primer pairs
designed to amplify exon-intron regions within the nSR100 target genes Daam1, Asph, Elmo2, and Dock 4 and as controls to the nontarget genes Myo5a (false
positive from microarray predictions) and Pbrm1. RT was omitted from the PCR reactions in lanes 2, 3, 7, and 8 to control for possible genomic DNA contam-
ination.Cell 138, 898–910, September 4, 2009 ª2009 Elsevier Inc. 905
Using in vivo CLIP, anti-nSR100 immunoprecipitates were
analyzed by RT-PCR assays to detect intron-exon regions over-
lapping five validated, nSR100-regulated AS events. In all cases,
immunoprecipitation of these regions was observed (Figure 5G;
representative examples are shown) and was UV and anti-
nSR100 antibody dependent (Figure 5G, compare lanes 4 and
5 with 9 and 10). Moreover, little to no anti-nSR100 immunopre-
cipitation was detected for three regions overlapping profiled AS
events that are not regulated by nSR100 (Figure 5G, lower two
panels, and data not shown).
The results described above provide evidence that nSR100
establishes neural-specific AS patterns by forming direct inter-
actions with its regulated target transcripts, as well as by
promoting increased expression of nPTB.
Figure 6. nSR100 Regulates Vertebrate
Nervous System and Sensory Organ Devel-
opment
(A–C) RNA in situ hybridization assays monitoring
ZnSR100 expression in the developing zebrafish
embryo.
(A and A0 ) expression at 24 hpf, lateral and frontal
views, respectively.
(B and B0) nSR100 expression at 36 hpf, lateral and
dorsal views, respectively.
(C and C0) nSR100 expression at 48 hpf, lateral and
dorsal views, respectively.
(D) p53 morpholino antisense oligonucleotide
(MO) control-injected embryo at 50 hpf.
(E) p53 + ZnSR100 MOspl-injected embryo at
50 hpf.
(F) p53 + ZnSR100 MOspl-injected embryo at
50 hpf, rescued through coinjection of ZnSR100
mRNA.
(G–I) RNA in situ hybridization assays monitoring
islet-1 expression in 50 hpf embryos. p53-MO-in-
jected control (G), nSR100spl morphant embryo
(H), and nSR100spl morphant embryo rescued
through coinjection of 20 pg ZnSR100 mRNA (I)
are shown.
(J–M) Confocal projections of trigeminal ganglion
in Tg(sensory:GFP) transgenic embryos. Control
embryo at 30 hpf (J), representative nSR100spl
morphant embryo at 30 hpf (K), control embryo
at 36 hpf (L), and representative nSR100spl mor-
phant embryo at 36 hpf (M) are shown.
(N) nSR100-regulated alternative exons conserved
between zebrafish and mouse display altered
splicing patterns in nSR100spl morphant embryos,
relative to control embryos. Total RNA was isolated
from the heads of wild-type and nSR100spl mor-
phant embryos at 50 hpf, and semiquantitative
RT-PCR was performed to analyze AS patterns.
Percent exon inclusion values are shown below
each lane.
A Role for nSR100 in Nervous
System Development
The high degree of homology (Figure S2)
between mammalian and zebrafish
nSR100 (ZnSR100) indicates that its
function is likely conserved throughout
the vertebrate lineage. Accordingly, we next examined the distri-
bution and function of ZnSR100 in developing zebrafish
embryos.
ZnSR100 expression was examined by whole-mount RNA
in situ hybridization and no expression was detected prior to
gastrulation stages (data not shown). At 24 hr postfertilization
(hpf), significant expression was observed in the developing
brain, including the tectum (tec) and telencephalon (tel) (Figures
6A and 6A0). Expression was also observed around the trigeminal
ganglion (tg), at the mid-hindbrain boundary, and throughout the
hindbrain (hb). At 36 hpf, additional ZnSR100 expression was
observed in the cerebellum (cb) and within the retina (r) (Figures
6B and 6B0). At 48 hpf, stronger and more widespread ZnSR100
expression was detected throughout the developing eyes and906 Cell 138, 898–910, September 4, 2009 ª2009 Elsevier Inc.
brain (Figures 6C and 6C0). These results are highly consistent
with the expression and immunostaining data for mammalian
nSR100 (Figures 1 and 2).
To knock down ZnSR100 function we injected single cell-
staged embryos with an antisense morpholino oligonucleotide
(MOspl) targeted against the 50 splice site of exon 5 of
ZnSR100 pre-mRNA. Severe neural degeneration was observed
throughout the brain and spinal cord of 24 hpf embryos (data not
shown). This phenotype resembles a common off-target effect of
MO injection caused by induction of the p53-dependent cell
death pathway and can be circumvented by knockdown of
p53 activity (Robu et al., 2007). We therefore coinjected MOspl
together with p53-MO. RT-PCR assays confirmed that the
MOspl oligonucleotide caused nearly complete disruption of
splicing of ZnSR100 exon 5 to exon 6 (Figure S12). We therefore
expected efficient knockdown of ZnSR100 function.
At 50 hpf, control embryos injected with relatively high levels of
p53-MO alone appeared phenotypically normal (Figure 6D and
data not shown). In contrast, over 90% of MOspl-injected ‘‘mor-
phant’’ embryos exhibited consistent developmental abnormal-
ities that included a curved body axis and expanded brain ventri-
cles (n = 200; Figures 6E and S13). To examine neuronal
differentiation in nSR100 morphant embryos, we performed
RNA in situ hybridization for islet-1, a LIM homeodomain-
containing transcription factor that is an early marker for the
differentiation of diverse neuronal populations. At 24 hpf, islet-1
expression in ZnSR100 morphants appeared identical to p53-
MO-injected controls (Figure S14). Strikingly, islet-1 expression
in 50 hpf nSR100 morphant embryos was markedly reduced,
consistent with a severe disruption to neuronal differentiation
(Figures 6G and 6H; compare to Figure S14). These effects
were not due to significant developmental delay, as general
embryonic morphogenesis and patterning appeared normal in
nSR100 morphant embryos (Figure S13).
Similar phenotypes as observed in MOspl morphants were
observed after injection of a translation-blocking morpholino
targeted to the start codon of ZnSR100 (MOatg; data not
shown). Moreover, the morphological and neuronal differentia-
tion defects observed in ZnSR100 MOspl-injected embryos
could be rescued by coinjecting in vitro transcribed, capped
ZnSR100 mRNA (n = 42/52; Figures 6F and 6I). These results
further indicate that the observed phenotypes are not due to
off-target effects of MO injection, but rather are the specific
result of reduced ZnSR100 expression.
We next examined the consequence of knocking down
ZnSR100 function on the axonal extension and branching (arbor-
ization) of trigeminal sensory neurons. Trigeminal neurons are
among the first neurons to develop in vertebrates and begin to
display marked arborization at 16 hpf in zebrafish embryos.
To visualize axon arbors in vivo, we utilized Tg(sensory:GFP)
transgenic animals that drive GFP expression in Rohon-Beard
and trigeminal sensory neurons (Sagasti et al., 2005). Confocal
projections of trigeminal ganglia in control embryos at 30 hpf
(n = 7) and 36 hpf (n = 6) revealed multiple axonal projections
and an elaborate array of peripheral sensory arbors (Figures 6J
and 6L). In contrast, visualization of trigeminal sensory neurons
in ZnSR100 morphant embryos at 30 hpf (n = 7) and 36 hpf
(n = 6) revealed obvious defects in the formation of peripheralsensory arbors (Figures 6K and 6M). As before, these defects
could be rescued by coinjection of ZnSR100 mRNA (Figure S15).
Together, the results described above indicate a critical role for
nSR100 in neuronal differentiation in a whole animal context.
Finally, we analyzed the effects of MOspl disruption of
ZnSR100 on the AS levels of exons that are conserved between
zebrafish and mouse. Reduced inclusion levels were observed
for 6/7 exons that require nSR100 for inclusion in Neuro2A cells,
whereas two conserved alternative exons that are not regulated
by nSR100 in Neuro2a cells were not affected (Figure 6N and
data not shown). These results, which additionally support the
specificity of the effects of MOspl-targeting of ZnSR100 func-
tion, lead us to conclude that nSR100 regulates a program of
AS events that is highly conserved between zebrafish and
mammals.
DISCUSSION
A Neural- and Vertebrate-Specific Activator
of Alternative Splicing
The discovery and characterization of nSR100 reveals how a
large set of brain-specific exons are positively regulated in genes
that play numerous critical roles in vertebrate nervous system
development. While the evolutionary origin of nSR100 is unclear,
its short region of perfect identity with an SRm300 splicing
factor-like protein and extensive SR/RS repeat regions (Figure 1)
suggests that a duplication event involving an ancestral
SRm300-related gene may have led to the emergence of
nSR100. Subsequently, nSR100 may have been coadopted
with nPTB and other factors to afford the evolution of increased
neural AS complexity. Consistent with the evolution of extensive
codependent functions, nPTB also appears to have evolved
around the time of emergence of the vertebrate lineage (Bar-
bosa-Morais et al., 2006), and both proteins are highly enriched
in postmitotic neurons relative to glial cells (Figure 2) (Boutz et al.,
2007). These observations support the conclusion that the emer-
gence of nSR100 played a critical role in the evolution of the
expanded proteomic and functional complexity of the vertebrate
nervous system.
Global and Local Roles for nSR100
in Neural-Specific Alternative Splicing
The global regulatory properties of nSR100 and its remarkably
tight neural-restricted expression pattern indicate that it serves
as the specificity factor for 11% of mammalian nervous
system-specific AS events (refer to the Supplemental Experi-
mental Procedures). While functioning in conjunction with
nPTB, it is possible that nSR100 also functions with other
neural-enriched AS regulators such as members of the Fox,
CUGBP/CELF, and MBNL families of proteins. In fact, our motif
analyses in the present study reveal putative binding sites for
several of these factors in the intronic sequences flanking
nSR100-regulated exons (Figure S7). Moreover, coimmunopre-
cipitation experiments reveal that nSR100 associates with
specific SR proteins recognized by the pan-SR-specific mono-
clonal antibody mAb104 (J.A.C, D.O, B.R., and B.J.B, unpub-
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Together, these findings support a model (Figure 7) in which
nSR100 binds to target transcripts and functions with nPTB
and possibly other factors to overcome the repressive forces
of PTB during neural differentiation. This model is consistent
with emerging evidence for complex regulatory codes involving
combinations of different cis-regulatory elements bound by cor-
responding trans-acting factors in the regulation of neural-
specific AS events (Li et al., 2007). It is also consistent with the
established properties of SR family and SR-related proteins,
which interact with one another in different contexts to form posi-
tive-acting regulatory complexes on pre-mRNA (Lin and Fu,
2007). Indeed, the relatively large size of nSR100 and its exten-
sive RS domains suggests that it could form important interac-
tions with many splicing factors to promote exon inclusion in
neural cells.
Functions of an nSR100-Regulated Neural
Exon Network
Many nSR100-regulated exons are found in genes required for re-
modeling of the cytoskeleton, including several with neuronal
GTPase activity. Rho family small GTPases are key regulators of
the actin cytoskeleton during neuronal morphogenesis and
require guanine nucleotide exchange factors for activation
(Govek et al., 2005). Besides Daam1, which is required for the
activation of the GTPase RhoA (Habas et al., 2001), other
Figure 7. Model for nSR100-Dependent Regu-
lation of Neural-Specific Alternative Splicing
nSR100 activates the inclusion of neural-specific alter-
native exons in a regulatory circuit that involves the
switch between PTB and nPTB proteins. In one part
of this circuit, nSR100 promotes the inclusion of
exon 10 in nPTB pre-mRNA (green solid arrows),
leading to the increased expression of nPTB relative
to PTB, which facilitates but is not sufficient for
neuronal-specific alternative exon inclusion. In the
presence of nPTB and other factors, such as SR family
and/or SR-related proteins, nSR100 forges positive-
acting interactions by binding to its regulated target
transcripts.
nSR100-regulated exons are located in
Dock4 (a guanine nucleotide exchange
factor) and its binding partner Elmo2 (see
Figure 3). A complex of Dock4, Elmo2, and
adaptor protein CrkII promotes dendritic
growth and branching in hippocampal
neurons through the activation of another
small GTPase, Rac. These observations are
consistent with our finding that GTP-based
signaling represents one of the most highly
enriched functions associated with genes
that display nervous system-specific AS
(Fagnani et al., 2007). Detailed annotation of
the genes with nSR100-regulated exons that
have the potential to alter coding sequences
reveals that approximately half of the corre-
sponding proteins can be assembled into
a network, based on prior published evidence
for protein-protein interactions (J. Ellis, J.A.C, and B.J.B, unpub-
lished data). More than half of the regulated exons in this model for
an nSR100-regulated network are conserved between human
and mouse. It is therefore tempting to speculate that nSR100
target exons function in an elaborate protein-protein interaction
network that is critical for remodeling of the cytoskeleton during
neuronal differentiation. Future studies will be directed at eluci-
dating the functions of nSR100-regulated AS events.
EXPERIMENTAL PROCEDURES
Identification of RS Domain Protein Genes
Mammalian RS domain genes with tissue-restricted expression patterns were
identified using a two-step computational procedure (Figure 1A) coupled to an
analysis of mouse mRNA expression profiling data from 50 different cell and
tissue types. Refer to Table S1 for a complete annotated list of identified RS
domain genes.
Microarray Hybridization, Data Extraction, and Analysis
AS microarray profiling was performed using a new 244 K feature custom
oligonucleotide microarray (Agilent Technologies Inc.) representing 6700
cassette AS events from 5500 mouse genes. Mining of the AS events and
design of the microarray probe sets was performed essentially as described
in Pan et al. (2004).
RT-PCR Assays
Nonradioactive RT-PCR assays were performed using the OneStep kit
(QIAGEN), and radioactive RT-PCR assays were performed essentially as908 Cell 138, 898–910, September 4, 2009 ª2009 Elsevier Inc.
described previously (Calarco et al., 2007). Primer sequences are available
upon request.
siRNA and Minigene Reporter Transfections
Neuro2a cells were transfected with SMART-pool siRNAs (Dharmacon) using
Dharmafect (Dharmacon), as recommended by the manufacturer. Daam1
minigene reporters and expression plasmids were transfected using Lipofect-
amine 2000 (Invitrogen), as recommended by the manufacturer. Total RNA
was collected 48 hr after transfection and isolated using RNeasy kits
(QIAGEN).
Recombinant Proteins and RNA Gel Mobility Shift Assays
Purified recombinant proteins were incubated with in vitro-transcribed, radio-
labeled transcripts and separated by nondenaturing PAGE. Gels were dried
and exposed to X-ray film (Kodak).
In Vitro Splicing Assays
In vitro splicing assays performed in 20 ml contained 1.5 mM ATP, 5 mM crea-
tine phosphate, 5 mM DTT, 3 mM MgCl2, 2.6% PVA, RiboLock RNase inhibitor
(Fermentas), 10 ng of splicing substrate, 40–60 mg of Weri or HeLa splicing
extract, and up to 12 mL buffer E. Reactions were incubated at 30C for 1 hr
prior to RNA isolation. Spliced products were amplified by RT-PCR assays
using primers specific for MINX exons. RT-PCR products were resolved on
a 2% ethidium bromide-stained agarose gel stained and visualized using the
Gel Doc imaging system (Bio-Rad).
In Vitro Crosslinking and Immunoprecipitation
Weri cell extract was preincubated under splicing conditions in the presence
of 60 ng/mL tRNA for 8 min at 30C. Radiolabeled RNA substrate was added
followed by incubation for 15 min at 30C. Samples were irradiated with UV
light for 10 min on ice in a UV Stratalinker 1800 (Stratagene) at a distance of
1.5 cm from the light source, followed by digestion with 0.1 mg of RNaseA
for 15 min at 37C. Samples were separated by SDS-PAGE and analyzed by
autoradiography.
Zebrafish Embryo In Situ Hybridization
and Oligonucleotide Injections
RNA in situ hybridizations were performed using nitroblue-tetrazolium chloride
and 5-bromo-4-chloro-indolyl-phosphate detection (Roche). Embryo staging
and analyses were performed using the TLxAB background. One cell stage
embryos were injected with 6 ng of antisense morpholino oligonucleotide
and 25 pg of capped ZnSR100 mRNA synthesized using the mMESSAGE
system (Ambion) as per the manufacturer’s recommendation.
ACCESSION NUMBERS
Preprocessed probe intensity scores for all AS microarray data is available
from the GEO database under accession number GSE16187.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, three
tables, and 15 figures can be found with this article online at http://www.cell.
com/supplemental/S0092-8674(09)00711-9.
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